Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04032639
Other study ID # 1000061983
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date May 30, 2019
Est. completion date May 2024

Study information

Verified date September 2022
Source The Hospital for Sick Children
Contact Jill K Hamilton, MD
Phone 416-813-5115
Email jill.hamilton@sickkids.ca
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Individuals with Prader-Willi Syndrome (PWS) have increased hunger and food seeking behaviour, as well as learning (cognitive) challenges. In addition, some patients with PW been shown to have low cortisol production, particularly in stressful situations. However, research examining how hormonal, cognitive, and psychological factors are interrelated PWS is limited. To address this gap in knowledge, the goal of this project is to understand how changes in brain regions involved in controlling food intake and cognitive processes are related to changes in hormones regulating appetite, the stress hormone cortisol, and performance on neuropsychological tests.


Description:

Prader-Willi Syndrome (PWS) is characterized by hyperphagia, although the degree of food seeking can vary between individuals. This behaviour may be moderated by hormonal, neurocognitive, and psychological factors; however, data assessing these factors in an integrated fashion is scarce. The proposed research will address and identify relationships between three major challenges in PWS: 1) dysregulated feeding behaviour, 2) cognitive performance, and 3) chronic stress. The investigators will measure brain response to food cues, during a cognitive task, and at rest using magnetoencephalography (MEG) in adolescents with PWS and BMI-matched controls. This is an innovative design as previous studies in this population used only functional magnetic resonance imaging (fMRI) to examine food cue reactivity, which does not directly measure neuronal activity and lacks temporal-sensitivity. In contrast, MEG directly records neural firing and combines high spatial resolution with exquisite temporal resolution, allowing us to measure functional connectivity between brain regions. Importantly, MEG is also patient-friendly with fewer contraindications than MRI. To assess cognitive function, the investigators will utilize gold-standard neuropsychological measures, as well as emotional and social behavioural functioning. Lastly, the investigators will assess hair cortisol, which is a reflection of long term, month-by-month cortical exposure. This new area of research will explore neurobiological and cognitive mechanisms controlling feeding behaviour in PWS.


Recruitment information / eligibility

Status Recruiting
Enrollment 48
Est. completion date May 2024
Est. primary completion date May 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 7 Years to 16 Years
Eligibility Inclusion Criteria: - Genetically diagnosed PWS (study population) - Adolescents matched for age, sex, and BMI-percentile (controls) Exclusion Criteria: - Past or current history of alcoholism or consistent drug use - Current untreated major psychiatric illness as defined by the DSM-V criteria - Medications that decrease alertness (that cannot be held on the days of testing) - History of recent major head trauma - Current pregnancy - Diagnosis of diabetes - Current or recent smoker (i.e. >2 cigarettes/week during past year) - History of metal in body (shrapnel, metal slivers, unremovable metal adornments, clips, top braces, pacemaker) - Use of glucocorticoid medications

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (3)

Lead Sponsor Collaborator
The Hospital for Sick Children Holland Bloorview Kids Rehabilitation Hospital, University of Western Ontario, Canada

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Other Relationships between neuropsychological function and neuronal activity during the food cue reactivity task To compare how neuropsychological function correlate with neuronal activity in PWS compared to controls 2 years
Other Relationships between neuropsychological function and neuronal activity during the response inhibition task To compare how neuropsychological function correlate with neuronal activity in PWS compared to controls 2 years
Primary Neuronal activity during the food cue reactivity task To compare neuronal activity between PWS and controls during the food cue task 2 years
Secondary Relationships between appetite hormone response and neuronal activity during the food cue task To compare how appetite hormones correlate with neuronal activity in PWS compared to controls 2 years
Secondary Relationships between cortisol and neuronal activity during the food cue reactivity task To compare how stress correlates with neuronal activity in PWS compared to controls 2 years
Secondary Neuronal activity during the emotional processing task To compare neuronal activity between PWS and controls during the emotional processing task 2 years
Secondary Neuronal activity during resting state To compare neuronal activity between PWS and controls during resting state 2 years
Secondary Neuronal activity during the response inhibition task To compare neuronal activity between PWS and controls during the response inhibition task 2 years
Secondary Relationships between neuropsychological function and neuronal activity during the emotional processing task To compare how neuropsychological function correlate with neuronal activity in PWS compared to controls 2 years
Secondary Relationships between cortisol and neuronal activity during the emotional processing task To compare how stress correlates with neuronal activity in PWS compared to controls 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05032326 - Long-term Interventional Follow-up Study of Children With Prader-Willi Syndrome Included in the OTBB3 Clinical Trial Phase 3
Completed NCT04526379 - Study of Emotion and Cognition Abilities of Children With PWS and Proposition of an Innovative Remediation N/A
Terminated NCT03458416 - A Study to Assess the Long-Term Safety of Pharmaceutical Grade Synthetic Cannabidiol Oral Solution in Participants With Prader-Willi Syndrome Phase 2
Completed NCT03718416 - Natural History Study of Serious Medical Events in PWS
Completed NCT05322096 - Study to Evaluate Efficacy, Safety, and Tolerability of RGH-706 in Prader-Willi Syndrome Phase 2
Completed NCT02205450 - Growth Hormone in Children Under 2 Years With Prader-Willi in Hospital of Sabadell
Terminated NCT02179151 - Double-Blind, Placebo Controlled, Phase 3 Trial of ZGN-440 (Beloranib) in Obese Subjects With Prader-Willi Syndrome Phase 3
Completed NCT00375089 - Characteristics of Prader-Willi Syndrome and Early-onset Morbid Obesity N/A
Completed NCT00004351 - Study of Phenotype and Genotype Correlations in Patients With Contiguous Gene Deletion Syndromes N/A
Recruiting NCT05938543 - Cerebellar TMS and Satiety in Prader-Willi Syndrome N/A
Suspended NCT05879614 - An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) Phase 2
Recruiting NCT03031626 - Oxygen Versus Medical Air for Treatment of CSA in Prader Will Syndrome Phase 4
Withdrawn NCT04086810 - An Open-Label Study of DCCR Tablet in Patients With PWS Phase 3
Completed NCT02629991 - Oxytocin vs. Placebo for the Treatment Hyperphagia in Children and Adolescents With Prader-Willi Syndrome Phase 2
Recruiting NCT02297022 - Deep Brain Stimulation for the Treatment of Obesity in Patients With Prader-Willi Syndrome Phase 1
Not yet recruiting NCT02263781 - PREPL in Health and Disease N/A
Completed NCT00551343 - Gut Derived Hormones, Body Composition and Metabolism in Prader-Willi Syndrome N/A
Recruiting NCT06448871 - Ultrasound to Assess Sarcopenia in Prader Willi Syndrome
Enrolling by invitation NCT03655223 - Early Check: Expanded Screening in Newborns
Recruiting NCT05939453 - Impact of Bright Light Therapy on Prader-Willi Syndrome N/A